The global gene editing market size is accounted at USD 10.77 billion in 2025 and is forecasted to hit around USD 40.10 billion by 2034, representing a CAGR of 15.74% from 2025 to 2034. The North America market size was estimated at USD 4.56 billion in 2024 and is expanding at a CAGR of 15.73% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Gene Editing Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Gene Editing Market, by Product & Services
8.1.1. Reagents & Consumables
8.1.1.1. Market Revenue and Forecast
8.1.2. Software & Systems
8.1.2.1. Market Revenue and Forecast
8.1.3. Services
8.1.3.1. Market Revenue and Forecast
9.1. Gene Editing Market, by Technology
9.1.1. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
9.1.1.1. Market Revenue and Forecast
9.1.2. Transcription Activator-Like Effector Nuclease (TALEN)
9.1.2.1. Market Revenue and Forecast
9.1.3. Zinc Finger Nuclease (ZFN)
9.1.3.1. Market Revenue and Forecast
9.1.4. Antisense
9.1.4.1. Market Revenue and Forecast
9.1.5. Other technologies
9.1.5.1. Market Revenue and Forecast
10.1. Gene Editing Market, by Application
10.1.1. Cell Line Engineering
10.1.1.1. Market Revenue and Forecast
10.1.2. Genetic Engineering
10.1.2.1. Market Revenue and Forecast
10.1.3. Drug Discovery & Development
10.1.3.1. Market Revenue and Forecast
10.1.4. Other Applications
10.1.4.1. Market Revenue and Forecast
11.1. Gene Editing Market, by End-user
11.1.1. Pharmaceutical and Biotechnology Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Academic and Research Institutes
11.1.2.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product & Services
12.1.2. Market Revenue and Forecast, by Technology
12.1.3. Market Revenue and Forecast, by Application
12.1.4. Market Revenue and Forecast, by End-user
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product & Services
12.1.5.2. Market Revenue and Forecast, by Technology
12.1.5.3. Market Revenue and Forecast, by Application
12.1.5.4. Market Revenue and Forecast, by End-user
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product & Services
12.1.6.2. Market Revenue and Forecast, by Technology
12.1.6.3. Market Revenue and Forecast, by Application
12.1.6.4. Market Revenue and Forecast, by End-user
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product & Services
12.2.2. Market Revenue and Forecast, by Technology
12.2.3. Market Revenue and Forecast, by Application
12.2.4. Market Revenue and Forecast, by End-user
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product & Services
12.2.5.2. Market Revenue and Forecast, by Technology
12.2.5.3. Market Revenue and Forecast, by Application
12.2.5.4. Market Revenue and Forecast, by End-user
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product & Services
12.2.6.2. Market Revenue and Forecast, by Technology
12.2.6.3. Market Revenue and Forecast, by Application
12.2.6.4. Market Revenue and Forecast, by End-user
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product & Services
12.2.7.2. Market Revenue and Forecast, by Technology
12.2.7.3. Market Revenue and Forecast, by Application
12.2.7.4. Market Revenue and Forecast, by End-user
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product & Services
12.2.8.2. Market Revenue and Forecast, by Technology
12.2.8.3. Market Revenue and Forecast, by Application
12.2.8.4. Market Revenue and Forecast, by End-user
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product & Services
12.3.2. Market Revenue and Forecast, by Technology
12.3.3. Market Revenue and Forecast, by Application
12.3.4. Market Revenue and Forecast, by End-user
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product & Services
12.3.5.2. Market Revenue and Forecast, by Technology
12.3.5.3. Market Revenue and Forecast, by Application
12.3.5.4. Market Revenue and Forecast, by End-user
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product & Services
12.3.6.2. Market Revenue and Forecast, by Technology
12.3.6.3. Market Revenue and Forecast, by Application
12.3.6.4. Market Revenue and Forecast, by End-user
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product & Services
12.3.7.2. Market Revenue and Forecast, by Technology
12.3.7.3. Market Revenue and Forecast, by Application
12.3.7.4. Market Revenue and Forecast, by End-user
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product & Services
12.3.8.2. Market Revenue and Forecast, by Technology
12.3.8.3. Market Revenue and Forecast, by Application
12.3.8.4. Market Revenue and Forecast, by End-user
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product & Services
12.4.2. Market Revenue and Forecast, by Technology
12.4.3. Market Revenue and Forecast, by Application
12.4.4. Market Revenue and Forecast, by End-user
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product & Services
12.4.5.2. Market Revenue and Forecast, by Technology
12.4.5.3. Market Revenue and Forecast, by Application
12.4.5.4. Market Revenue and Forecast, by End-user
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product & Services
12.4.6.2. Market Revenue and Forecast, by Technology
12.4.6.3. Market Revenue and Forecast, by Application
12.4.6.4. Market Revenue and Forecast, by End-user
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product & Services
12.4.7.2. Market Revenue and Forecast, by Technology
12.4.7.3. Market Revenue and Forecast, by Application
12.4.7.4. Market Revenue and Forecast, by End-user
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product & Services
12.4.8.2. Market Revenue and Forecast, by Technology
12.4.8.3. Market Revenue and Forecast, by Application
12.4.8.4. Market Revenue and Forecast, by End-user
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product & Services
12.5.2. Market Revenue and Forecast, by Technology
12.5.3. Market Revenue and Forecast, by Application
12.5.4. Market Revenue and Forecast, by End-user
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product & Services
12.5.5.2. Market Revenue and Forecast, by Technology
12.5.5.3. Market Revenue and Forecast, by Application
12.5.5.4. Market Revenue and Forecast, by End-user
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product & Services
12.5.6.2. Market Revenue and Forecast, by Technology
12.5.6.3. Market Revenue and Forecast, by Application
12.5.6.4. Market Revenue and Forecast, by End-user
13.1. Beren Therapeutics
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Agilent Technologies
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Creative Biogene
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Thermo Fisher-Scientific
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Synthego
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Integrated DNA Technologie
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Bean Therapeutics
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Intellia Therapeutics
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Lonza
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Horizon Discovery Group plc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample